BLSM· Health Care› Biotechnology

BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. More about the company

$15.81

+1.35% today

$503M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

—

Edge

—

Is BLSM early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-08-07 → 2026-10-22

S? 11w

2026-08-072026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 11w current

Total tracked: 11 weeks across 1 stage run.

BLSM among Biotechnology566th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…566	BLSMBlossomHill Therapeutics, Inc.	—	—	−29.2%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 11

1w13w26w

Week 11, early Stage 2

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.48x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.2%

—

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 11 · Vol 0.48x

2026-10-21S—

Wk 11 · Vol 0.35x

2026-10-20S—

Wk 11 · Vol 0.34x

2026-10-19S—

Wk 11 · Vol 0.76x

2026-10-16S—

Wk 10 · Vol —x

2026-10-15S—

Wk 10 · Vol —x

2026-10-14S—

Wk 10 · Vol —x

2026-10-13S—

Wk 10 · Vol —x

2026-10-12S—

Wk 10 · Vol —x

2026-10-09S—

Wk 9 · Vol —x

2026-10-08S—

Wk 9 · Vol —x

2026-10-07S—

Wk 9 · Vol —x

Moving averages & range

50 DMA

$19.07

200 DMA

—

52W High

—

52W Low

—

5D Low

$13.94

Resistance levels (recent highs)

20d High

$21.37

60d High

—

120d High

—

250d High

—

Next resistance

+35.2%

to 20d High

Dividend Yield

0.00%

P/B -0.3

BlossomHill Therapeutics: quick answers

Which sector and industry is BlossomHill Therapeutics in?

BlossomHill Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.